The pandemic was an intense microcosm of some of our wider healthcare challenges and focused attention on areas that can be improved. There is a need…
In Conversation
... if you compare [malaria] to other infectious diseases, which have received a lot of global attention, whether that is HIV or TB, or even the…
... 60-70 percent of current Italian needs are covered self-sufficiently. In Italy plasma is for the Italians’ needs and not to be sold to other countries.…
Within reproductive medicine we are the leaders in the Italian market and one of the top 10 markets worldwide, still we want to be higher in…
Over the past ten years, our growth has been 100 percent organic, fuelled by Accord-developed products and in-licensing and underpinned by a very committed, enthusiastic and…
Organon took a portfolio of more than 60 products, 9,000+ employees and over USD 6 billion in revenue; it is a large and complex organization that…
... our R&D department, which is big and growing, participates in 80 percent of MSD’s global clinical trials, making the affiliate number one in Europe by…
AIFA has always favoured innovation and, in this context, has defined specific criteria with the aim of guaranteeing quick access to medicines that have a clear…
The MEA region has a lot of potential, as we see big projects underway and investments in healthcare in major markets.
... if high drug prices are the problem – and this administration says that a lot – then generics and biosimilars are the solution. I think…
[COVID] forced us to look at how our systems and processes were able to deal with such high demand. . . we transformed the way we…
... the Ichnos team has further accelerated our clinical stage pipeline in haematological malignancies to better position the firm and prepare it to host new investors…
